European CHMP Formally Adopts Negative Opinion On Oncophage(R)

tD33NAt

Active member
Joined
Mar 24, 2008
Messages
12,519
Reaction score
0
Points
36
Antigenics Inc. (NASDAQ: AGEN) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer).


H18aWCgGQIw


More...
 
Back
Top